Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies and distribution centers through June 2027. “We are pleased to continue our long-standing relationship with CVS Health and value the shared commitment of improving health outcomes for all patients,” said Brian Tyler, chief executive officer, M

McKesson Corporation Extends Pharmaceutical Distribution Agreement With CVS Health

Carlsberg AS

Hyatt Hotels

As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select Hyatt Hotels (H), McKesson (MCK) and Carlsberg (CABGY) as these have seen rating upgrades recently.

3 Stocks With Upgraded Broker Ratings for Impressive Returns

Boeing

Raytheon Technologies

Could now be the time to buy these defensive stocks as the stock market hits fresh new 52-week lows today.

3 Defensive Stocks To Watch Before October 2022

Atmos Energy

Corteva Inc

National Fuel Gas

Here we mention four defensive stocks, namely Corteva (CTVA), Atmos Energy, National Fuel Gas Company and McKesson with strong prospects to beat the market whims.

4 Top-Ranked Defensive Stocks to Buy Amid Market Swings

Humana

Eli Lilly

Neurocrine Biosciences

Vertex Pharmaceuticals

S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared first on Investor's Business Daily.

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market

AstraZeneca

UnitedHealth Group

In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.

3 Medical Stocks Displaying Remarkable Relative Strength in 2022

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Here's Why You Should Buy McKesson (MCK) Stock Right Now

NextEra Energy

PepsiCo

Southern Company

We have narrowed our search to five low-beta high-yielding defensive stocks that have strong potential for the rest of 2022. These are: NEE, SO, PEP, CTVA and MCK.

Bet on These 5 Ultra-Defensive Stocks for the Rest of 2022

McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.

McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout

Caterpillar

Johnson & Johnson

Due to their well-established nature and track records of success, these companies are positioned to weather a dark fiscal cloud better than most.

Defense Wins Ballgames; 3 Blue-Chip Stocks To Consider

Hershey

Grab these four defensive stocks, namely Corteva (CTVA), Hershey (HSY), National Fuel Gas Company (NFG) and McKesson (MCK), which hold strong potential.

Beat the Market Vagaries With 4 Top-Ranked Defensive Bets

Drug distributor McKesson Corporation said on Monday it would acquire private pharma technology firm Rx Savings Solutions for up to $875 million.

McKesson to buy pharma tech firm Rx Savings for up to $875 mln

McKesson Corp. MCK, +1.53% said Monday it has reached an agreement to acquire Rx Savings Solutions for up to $875 million. Rx Savings Solutions is a prescription price transparency and benefit information company that serves about 17 million patients.

McKesson to acquire Rx Savings Solutions for up to $875 million

Acquisition aligns with McKesson's strategic growth focus by connecting biopharma and payer services to patients Acquisition extends leadership in access, affordability, and adherence solutions, leveraging McKesson's differentiated platform Acquisition of Rx Savings Solutions strengthens McKesson's purpose to advance health outcomes for all McKesson and Rx Savings Solutions share a commitment to making medication therapy more affordable and increasing medication adherence to improve outcomes Rx Savings Solutions' value proposition for employers, payers and patients is fortified by McKesson's scaled ecosystem of provider, pharmacy, and biopharma services Combined capabilities set the foundation for expansion of adherence, outcomes management, and evidence-based biopharma and payer services OVERLAND PARK, Kan. , Sept. 19, 2022 /PRNewswire/ -- McKesson Corporation (NYSE: MCK) today announced that it has signed a definitive agreement to acquire Rx Savings Solutions (RxSS), a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers, reaching more than 17 million current patients.

McKesson Signs Agreement to Acquire Rx Savings Solutions

Relative strength helps find winners when markets turn. But don't forget about this element to protect yourself from losses.

Relative Strength Wasn't Enough For MCK Stock

Boise Cascade

RCI Hospitality

Triton International

TotalEnergies SE

Boise Cascade (BCC), Triton International (TRTN), TotalEnergies (TTE), McKesson (MCK) and RCI Hospitality (RICK) seem compelling cheap picks amid volatility.

5 Dividend Growth Stocks to Buy Cheap

American Airlines

Beacon Roofing Supply

Builders FirstSource

CVR Energy

Broker-favorite stocks like American Airlines (AAL), CVR Energy (CVI), Builders FirstSource (BLDR), McKesson (MCK) and Beacon Roofing Supply (BECN) should be on investors' watch list amid flared-up inflation.

5 Broker-Friendly Stocks to Watch as Inflation Stays Red Hot

Con Ed

Realty Income Corp

The inflation data released on September 13 spooked markets as the S&P 500 and other constituents sold off.

3 defensive stocks to buy for the second half of 2022

CVS Health

Dow Inc

Kirby

Occidental Petroleum

Rush Enterprises

Schlumberger

Ronald Muhlenkamp is the founder and president of Muhlenkamp & Company, which was established in 1997 to manage private accounts for individuals and institutions.

These Are Ronald Muhlenkamp's Top 10 Holdings

Archer-Daniels-Midland Company

We have narrowed our search to five defensive stocks with growth potential for the rest of 2022. These are: NEE, SO, ADM, PEP, MCK.

Stay Safe With 5 Defensive Stocks in an Extremely Volatile 2022

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE:MCK) today announced that LeAnn B. Smith has been selected to become executive vice president and chief human resources officer (CHRO). Ms. Smith will succeed Tracy L. Faber, McKesson's current CHRO, who will be retiring after an accomplished 11-year tenure with McKesson. These changes are expected to be effective December 1, 2022. In her new role, Ms. Smith will report to Brian Tyler, chief executive officer (CEO), and serve as a membe

McKesson Names LeAnn B. Smith as Next Chief Human Resources Officer

Marathon Petroleum

Exxon Mobil

We have narrowed our search to five S&P 500 stocks that have popped year to date despite the index's bloodbath. These are: ADM, CTVA, MCK, MPC and XOM.

S&P 500 Likely to Trade Rangebound in September: 5 Picks

McKesson (MCK) reported earnings 30 days ago. What's next for the stock?

McKesson (MCK) Up 7.7% Since Last Earnings Report: Can It Continue?

J.B. Hunt Transport Services

Republic Services

Dividend growth stocks like TotalEnergies, J.B. Hunt, Archer-Daniels-Midland, McKesson and Republic Services seem like solid choices for September.

5 Dividend Growth Stocks to Beat September Slump

Ally Financial

Citigroup

The Oracle of Omaha has added a bunch of stocks that have lost value lately, but this one is standing out with its performance.

News for McKesson Stock (MCK)